Abbott's MitraClip Climbs EVEREST II: What Patients Are On The Other Side?
This article was originally published in The Gray Sheet
Executive Summary
Abbott's minimally invasive MitraClip device has the potential to control up to a $400 million worldwide market in the mitral valve repair space, analysts say, but questions remain on how the largely positive pivotal data reported last week will translate into market adoption
You may also be interested in...
CMS In Brief
Medicare updates: “Inherent reasonableness,” DRGs and more.
ACC Meeting In Brief
More on MitraClip
ACC Meeting In Brief
More on MitraClip